RS57278B1 - Antitelo-lek konjugat - Google Patents
Antitelo-lek konjugatInfo
- Publication number
- RS57278B1 RS57278B1 RS20180643A RSP20180643A RS57278B1 RS 57278 B1 RS57278 B1 RS 57278B1 RS 20180643 A RS20180643 A RS 20180643A RS P20180643 A RSP20180643 A RS P20180643A RS 57278 B1 RS57278 B1 RS 57278B1
- Authority
- RS
- Serbia
- Prior art keywords
- antibody
- drug conjugate
- conjugate
- drug
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title 1
- 229940049595 antibody-drug conjugate Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012225887 | 2012-10-11 | ||
EP13845596.9A EP2907824B1 (en) | 2012-10-11 | 2013-10-10 | Antibody-drug conjugate |
PCT/JP2013/006069 WO2014057687A1 (ja) | 2012-10-11 | 2013-10-10 | 抗体-薬物コンジュゲート |
Publications (1)
Publication Number | Publication Date |
---|---|
RS57278B1 true RS57278B1 (sr) | 2018-08-31 |
Family
ID=50477169
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20180643A RS57278B1 (sr) | 2012-10-11 | 2013-10-10 | Antitelo-lek konjugat |
RS20200226A RS60000B1 (sr) | 2012-10-11 | 2013-10-10 | Veznici za antitelo-lek konjugate |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20200226A RS60000B1 (sr) | 2012-10-11 | 2013-10-10 | Veznici za antitelo-lek konjugate |
Country Status (30)
Country | Link |
---|---|
US (5) | US10195288B2 (sr) |
EP (3) | EP3342785B1 (sr) |
JP (7) | JP5953378B2 (sr) |
KR (13) | KR101901558B1 (sr) |
CN (4) | CN109081871B (sr) |
AU (4) | AU2013328111B2 (sr) |
BR (3) | BR122021014365B1 (sr) |
CA (2) | CA3021435C (sr) |
CY (2) | CY1120363T1 (sr) |
DK (2) | DK2907824T3 (sr) |
ES (2) | ES2671644T3 (sr) |
HK (2) | HK1210477A1 (sr) |
HR (2) | HRP20180870T1 (sr) |
HU (2) | HUE039000T2 (sr) |
IL (5) | IL271760B (sr) |
LT (2) | LT2907824T (sr) |
MX (3) | MX364484B (sr) |
MY (1) | MY170251A (sr) |
NZ (4) | NZ746440A (sr) |
PH (2) | PH12015500667B1 (sr) |
PL (2) | PL2907824T3 (sr) |
PT (2) | PT2907824T (sr) |
RS (2) | RS57278B1 (sr) |
RU (1) | RU2664465C2 (sr) |
SG (2) | SG11201502887WA (sr) |
SI (2) | SI2907824T1 (sr) |
TR (1) | TR201809636T4 (sr) |
TW (5) | TWI696611B (sr) |
WO (1) | WO2014057687A1 (sr) |
ZA (2) | ZA201501825B (sr) |
Families Citing this family (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE039000T2 (hu) * | 2012-10-11 | 2018-12-28 | Daiichi Sankyo Co Ltd | Antitest-gyógyszer konjugát |
EP2910573B1 (en) * | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
CA2933666C (en) * | 2013-12-25 | 2021-08-03 | Sapporo Medical University | Anti-trop2 antibody-drug conjugate |
DK3466976T3 (da) * | 2014-01-31 | 2021-12-13 | Daiichi Sankyo Co Ltd | Anti-her2-antistof-lægemiddelkonjugat |
JP2017114763A (ja) * | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗cd98抗体−薬物コンジュゲート |
US11185594B2 (en) * | 2014-04-10 | 2021-11-30 | Daiichi Sankyo Company, Limited | (Anti-HER2 antibody)-drug conjugate |
KR102624244B1 (ko) * | 2014-04-10 | 2024-01-11 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
IL290959B2 (en) | 2015-06-29 | 2023-04-01 | Daiichi Sankyo Co Ltd | Preparations containing antibody-drug conjugates and methods for their production |
KR20180095828A (ko) * | 2015-12-24 | 2018-08-28 | 에이지씨 가부시키가이샤 | 수지 조성물, 기재 및 세포 배양 방법 |
EP3442574A4 (en) * | 2016-04-15 | 2019-12-11 | MacroGenics, Inc. | NOVEL B7-H3 BINDING MOLECULES, THEIR ANTIBODY-MEDICINAL CONJUGATES AND METHODS OF USE |
JP2019526529A (ja) * | 2016-06-08 | 2019-09-19 | アッヴィ・インコーポレイテッド | 抗b7−h3抗体及び抗体薬物コンジュゲート |
TWI762487B (zh) * | 2016-06-08 | 2022-05-01 | 美商艾伯維有限公司 | 抗-b7-h3抗體及抗體藥物結合物 |
TW201825524A (zh) * | 2016-09-20 | 2018-07-16 | 中國大陸商上海藥明生物技術有限公司 | 新型抗-pcsk9抗體 |
US11273155B2 (en) | 2016-12-12 | 2022-03-15 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
WO2018135501A1 (ja) * | 2017-01-17 | 2018-07-26 | 第一三共株式会社 | 抗gpr20抗体及び抗gpr20抗体-薬物コンジュゲート |
US20200061031A1 (en) | 2017-02-28 | 2020-02-27 | Kinki University | Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate |
TW202330036A (zh) | 2017-05-15 | 2023-08-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
TW201909926A (zh) * | 2017-08-04 | 2019-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | B7h3抗體-藥物偶聯物及其醫藥用途 |
CN109106951A (zh) * | 2017-08-18 | 2019-01-01 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
MA49987A (fr) | 2017-08-23 | 2020-07-01 | Daiichi Sankyo Co Ltd | Préparation de conjugué anticorps-médicament et lyophilisation associée |
KR102630307B1 (ko) | 2017-08-31 | 2024-01-29 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 신규 제조 방법 |
CA3073924C (en) * | 2017-08-31 | 2023-10-17 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
US11628223B2 (en) | 2017-09-29 | 2023-04-18 | Daiichi Sankyo Company, Limited | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines |
CN111542324B (zh) * | 2018-02-11 | 2023-09-12 | 四川科伦博泰生物医药股份有限公司 | 细胞毒性剂及其偶联物、其制备方法及用途 |
CA3100608A1 (en) | 2018-05-18 | 2019-11-21 | Daiichi Sankyo Co., Ltd. | Anti-muc1 antibody-drug conjugate |
US20210251994A1 (en) | 2018-06-15 | 2021-08-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
WO2020022363A1 (ja) | 2018-07-25 | 2020-01-30 | 第一三共株式会社 | 抗体-薬物コンジュゲートの効果的な製造方法 |
CA3107732A1 (en) | 2018-07-27 | 2020-01-30 | Daiichi Sankyo Company, Limited | Protein recognizing drug moiety of antibody-drug conjugate |
TWI822822B (zh) * | 2018-07-31 | 2023-11-21 | 日商第一三共股份有限公司 | 抗體-藥物結合物之用途 |
CA3108754A1 (en) | 2018-08-06 | 2020-02-13 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and tubulin inhibitor |
JP7481255B2 (ja) | 2018-08-23 | 2024-05-10 | 第一三共株式会社 | 抗体薬物複合体の感受性マーカー |
US20220008549A1 (en) | 2018-09-06 | 2022-01-13 | Daiichi Sankyo Company, Limited | Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof |
JPWO2020059772A1 (ja) | 2018-09-20 | 2021-08-30 | 第一三共株式会社 | 抗her3抗体−薬物コンジュゲート投与によるher3変異がんの治療 |
KR20210066833A (ko) * | 2018-09-26 | 2021-06-07 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 엑사테칸 유사체의 리간드-약물 접합체, 이를 위한 제조 방법, 및 이의 적용 |
AU2019351427A1 (en) | 2018-09-30 | 2021-04-15 | Changzhou Hansoh Pharmaceutical Co., Ltd. | Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof |
AU2019379418A1 (en) | 2018-11-14 | 2021-06-03 | Daiichi Sankyo Company, Limited | Anti-CDH6 antibody-pyrrolobenzodiazepine derivative conjugate |
SG11202106248XA (en) * | 2018-12-11 | 2021-07-29 | Daiichi Sankyo Co Ltd | Combination of antibody-drug conjugate with parp inhibitor |
EP3903828A4 (en) | 2018-12-21 | 2022-10-05 | Daiichi Sankyo Company, Limited | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A KINASE INHIBITOR |
WO2020191344A1 (en) | 2019-03-20 | 2020-09-24 | The Regents Of The University Of California | Claudin-6 bispecific antibodies |
WO2020191342A1 (en) | 2019-03-20 | 2020-09-24 | The Regents Of The University Of California | Claudin-6 antibodies and drug conjugates |
US20220211863A1 (en) * | 2019-03-29 | 2022-07-07 | Medimmune Limited | Compounds and conjugates thereof |
EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
CN111689980A (zh) * | 2019-05-26 | 2020-09-22 | 四川百利药业有限责任公司 | 一种喜树碱药物及其抗体偶联物 |
CN112138171A (zh) * | 2019-06-28 | 2020-12-29 | 上海复旦张江生物医药股份有限公司 | 抗体偶联药物、其中间体、制备方法及应用 |
JP7407845B2 (ja) * | 2019-06-28 | 2024-01-04 | シャンハイ フダン-チャンジャン バイオ-ファーマシューティカル カンパニー リミテッド | 抗体薬物複合体、その中間体、製造方法及び使用 |
MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
EP3996749A1 (en) | 2019-07-10 | 2022-05-18 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
CN112125915A (zh) * | 2019-09-18 | 2020-12-25 | 四川百利药业有限责任公司 | 一种喜树碱衍生物及其偶联物 |
EP4074345A4 (en) * | 2019-12-12 | 2023-10-25 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | ANTI-CLAUDINE ANTIBODY-DRUG CONJUGATE AND ITS PHARMACEUTICAL USE |
EP4079761A4 (en) * | 2019-12-16 | 2024-02-07 | Jiangsu Hengrui Medicine Co., Ltd. | ANTI-CEA ANTIBODIES EXATECAN ANALOG CONJUGATE AND ITS PHARMACEUTICAL USE |
EP4076434A1 (en) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
JP2023510905A (ja) | 2020-01-22 | 2023-03-15 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗trop-2抗体-エキサテカン類似体複合体及びその医薬用途 |
CA3168654A1 (en) | 2020-01-22 | 2021-07-29 | Shanghai Senhui Medicine Co., Ltd. | Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine |
KR20230004453A (ko) | 2020-02-25 | 2023-01-06 | 메디보스턴 리미티드 | 캄프토테신 유도체 및 이의 접합체 |
IL296124A (en) | 2020-03-06 | 2022-11-01 | Daiichi Sankyo Co Ltd | Conjugation of an antibody with a drug including a novel cyclic dinucleotide derivative |
WO2021190480A1 (zh) * | 2020-03-24 | 2021-09-30 | 上海翰森生物医药科技有限公司 | 抗体-药物偶联物及其医药用途 |
CN115103691A (zh) | 2020-03-25 | 2022-09-23 | 江苏恒瑞医药股份有限公司 | 一种含抗体药物偶联物的药物组合物及其用途 |
AU2021240756A1 (en) | 2020-03-25 | 2022-11-17 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-PSMA antibody-exatecan analogue conjugate and medical use thereof |
JP2023521956A (ja) | 2020-03-25 | 2023-05-26 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗体薬物複合体の調製方法 |
JPWO2021200131A1 (sr) | 2020-03-30 | 2021-10-07 | ||
AU2021289927A1 (en) * | 2020-06-08 | 2023-01-19 | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof |
AU2021298251A1 (en) | 2020-06-24 | 2023-02-02 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and ATR inhibitor |
JP2023542065A (ja) | 2020-06-24 | 2023-10-05 | アストラゼネカ ユーケー リミテッド | 抗体-薬物複合物及びcdk9阻害剤の組み合わせ |
WO2021260583A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
TW202216209A (zh) | 2020-06-24 | 2022-05-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及atm抑制劑之組合 |
WO2021260582A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and aurora b inhibitor |
CN116096906A (zh) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
US10997243B1 (en) | 2020-06-30 | 2021-05-04 | Snowflake Inc. | Supporting unstructured, semi-structured, and structured files |
US11361026B2 (en) | 2020-06-30 | 2022-06-14 | Snowflake Inc. | Accessing files in a database stage using a user defined function |
US11423081B1 (en) | 2020-06-30 | 2022-08-23 | Snowflake Inc. | Accessing files in a database stage using a user defined function |
BR112023000174A2 (pt) | 2020-07-06 | 2023-01-31 | Byondis Bv | Composto ligante-fármaco, conjugado anticorpo-fármaco, composição farmacêutica, e, uso de um composto |
WO2022011075A1 (en) * | 2020-07-10 | 2022-01-13 | VelosBio Inc. | Novel ror1 antibody immunoconjugates |
KR20230038738A (ko) * | 2020-07-13 | 2023-03-21 | 리제너론 파마슈티칼스 인코포레이티드 | 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도 |
KR20230041023A (ko) | 2020-07-17 | 2023-03-23 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 제조 방법 |
CN116194483A (zh) | 2020-08-13 | 2023-05-30 | 先天制药公司 | 使用抗cd73抗体的癌症治疗方法 |
WO2022033578A1 (zh) | 2020-08-13 | 2022-02-17 | 正大天晴药业集团股份有限公司 | 抗体药物偶联物 |
AU2021338014A1 (en) | 2020-09-02 | 2023-03-09 | Daiichi Sankyo Company, Limited | Novel endo-β-N-acetylglucosaminidase |
AU2021354823A1 (en) | 2020-09-30 | 2023-03-30 | Duality Biologics (Suzhou) Co., Ltd. | Antitumor compound, and preparation method therefor and use thereof |
WO2022074617A1 (en) | 2020-10-09 | 2022-04-14 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
IL302054A (en) * | 2020-10-12 | 2023-06-01 | Sichuan Baili Pharm Co Ltd | CAMPTOTHECIN DERIVATIVE AND ITS LIGAND-DRUG CONJUGATION |
EP4245321A1 (en) | 2020-11-11 | 2023-09-20 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with anti-sirpalpha antibody |
WO2022099762A1 (zh) * | 2020-11-12 | 2022-05-19 | 博瑞生物医药(苏州)股份有限公司 | 一种抗体偶联物中间体及其制备方法 |
EP4245322A1 (en) | 2020-11-12 | 2023-09-20 | Daiichi Sankyo Company, Limited | Treatment for mesothelioma through administration of anti-b7-h3 antibody-drug conjugate |
JP2023550533A (ja) * | 2020-12-18 | 2023-12-01 | シャンハイ フダン-チャンジャン バイオ-ファーマシューティカル カンパニー リミテッド | B7-h3を標的とする抗体薬物複合体、その製造方法と使用 |
KR20230121842A (ko) * | 2020-12-18 | 2023-08-21 | 상하이 후단-장지앙 바이오-파마슈티컬 컴퍼니 리미티드 | Trop2를 표적으로 하는 항체 약물 접합체, 이의 제조방법 및 용도 |
US20240066138A1 (en) * | 2020-12-23 | 2024-02-29 | Shanghai Ruotuo Biosciences Co., Ltd. | Antibody-drug conjugates, pharmaceutical compositions, and therapeutic applications |
EP4277665A1 (en) * | 2021-01-13 | 2023-11-22 | Memorial Sloan Kettering Cancer Center | Anti-dll3 antibody-drug conjugate |
CN114805377A (zh) * | 2021-01-29 | 2022-07-29 | 明慧医药(杭州)有限公司 | 适用于抗体-药物偶联物的毒素分子 |
TW202241454A (zh) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體-免疫賦活化劑共軛物之新穎製造方法 |
JP2024508081A (ja) | 2021-02-09 | 2024-02-22 | メディリンク セラピューティクス(スーチョウ)カンパニー,リミティド | 生物活性物質コンジュゲート、その調製方法及びその使用 |
KR20230157983A (ko) | 2021-03-12 | 2023-11-17 | 다이이찌 산쿄 가부시키가이샤 | 당사슬 및 당사슬을 포함하는 의약품의 제조 방법 |
TW202300148A (zh) * | 2021-03-17 | 2023-01-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 喜樹鹼衍生物的製備方法 |
BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
AU2022246895A1 (en) | 2021-03-31 | 2023-10-19 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
WO2022217022A1 (en) | 2021-04-10 | 2022-10-13 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
AU2022259314A1 (en) * | 2021-04-14 | 2023-11-30 | Genequantum Healthcare (Suzhou) Co., Ltd. | Linkers, conjugates and applications thereof |
EP4079327A1 (en) | 2021-04-22 | 2022-10-26 | Centaurus Polytherapeutics | Payloads for drug-conjugates and their use for treating cancer |
JP2024516631A (ja) | 2021-04-23 | 2024-04-16 | プロファウンドバイオ ユーエス カンパニー | 抗cd70抗体、そのコンジュゲートおよびこれを使用する方法 |
EP4332117A1 (en) * | 2021-04-26 | 2024-03-06 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-nectin-4 antibody and anti-nectin-4 antibody-drug conjugate, and medicinal user thereof |
CN113816969B (zh) * | 2021-04-30 | 2024-01-16 | 联宁(苏州)生物制药有限公司 | 依喜替康类化合物、其抗体药物偶联物及其应用 |
US11645243B2 (en) | 2021-06-07 | 2023-05-09 | Snowflake Inc. | Accessing files in a database stage using a user defined function |
CA3223304A1 (en) * | 2021-06-17 | 2022-12-22 | Minghui Pharmaceutical (Hangzhou) Limited | Antitumor compound and its application |
WO2023275025A1 (en) | 2021-06-28 | 2023-01-05 | Byondis B.V. | Conjugates comprising phosphoantigens and their use in therapy |
EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
CN113402584A (zh) * | 2021-07-06 | 2021-09-17 | 联宁(苏州)生物制药有限公司 | 一种抗体偶联药物连接子的中间体lnd1067-l1的合成方法 |
CN113527418B (zh) * | 2021-07-16 | 2022-05-03 | 成都普康唯新生物科技有限公司 | 一种ADC linker的制备方法 |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
KR20240038732A (ko) * | 2021-07-19 | 2024-03-25 | 제노 매니지먼트, 인크. | 면역접합체 및 방법 |
AU2022314086A1 (en) | 2021-07-21 | 2024-02-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition containing anti-trop2 antibody drug conjugate and use thereof |
TW202320861A (zh) | 2021-09-15 | 2023-06-01 | 日商第一三共股份有限公司 | 以抗體-藥物結合物治療耐化療的癌症之方法 |
CA3234692A1 (en) | 2021-09-30 | 2023-04-06 | Ajinomoto Co., Inc. | Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound used in production of the same or salts thereof |
IL312237A (en) | 2021-10-18 | 2024-06-01 | Daiichi Sankyo Co Ltd | Anti-CD37 antibody-drug conjugate |
WO2023083381A1 (zh) | 2021-11-15 | 2023-05-19 | 成都百利多特生物药业有限责任公司 | 双特异性抗体-喜树碱类药物偶联物及其医药用途 |
US11814394B2 (en) * | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
AU2022392822A1 (en) | 2021-11-18 | 2024-05-02 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
WO2023092099A1 (en) | 2021-11-19 | 2023-05-25 | Ardeagen Corporation | Gpc3 binding agents, conjugates thereof and methods of using the same |
IL312728A (en) | 2021-11-30 | 2024-07-01 | Daiichi Sankyo Co Ltd | Antibodies masked in protease-wells |
AU2022402061A1 (en) | 2021-12-03 | 2024-07-11 | Systimmune, Inc. | Anti-human trop2 antibody-camptothecin drug conjugate and medical use thereof |
CN116333135A (zh) * | 2021-12-24 | 2023-06-27 | 百奥泰生物制药股份有限公司 | 抗FRα抗体及其抗体药物偶联物和用途 |
TW202339805A (zh) | 2021-12-28 | 2023-10-16 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及atr抑制劑之組合 |
TW202333800A (zh) | 2021-12-28 | 2023-09-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及rasg12c抑制劑之組合 |
WO2023126297A1 (en) | 2021-12-30 | 2023-07-06 | Byondis B.V. | Antifolate linker-drugs and antibody-drug conjugates |
WO2023138635A1 (zh) * | 2022-01-18 | 2023-07-27 | 甘李药业股份有限公司 | 一种依喜替康衍生物-抗体偶联物及其医药用途 |
WO2023173026A1 (en) | 2022-03-10 | 2023-09-14 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
WO2023175483A1 (en) | 2022-03-16 | 2023-09-21 | Astrazeneca Uk Limited | A scoring method for an anti-trop2 antibody‑drug conjugate therapy |
TW202400140A (zh) | 2022-04-27 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合 |
TW202400650A (zh) | 2022-05-11 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體與cd47抑制劑之組合 |
WO2023228095A1 (en) | 2022-05-24 | 2023-11-30 | Daiichi Sankyo Company, Limited | Dosage regimen of an anti-cdh6 antibody-drug conjugate |
WO2023237050A1 (en) * | 2022-06-09 | 2023-12-14 | Beigene, Ltd. | Antibody drug conjugates |
CN116789733A (zh) * | 2022-07-05 | 2023-09-22 | 上海药明合联生物技术有限公司 | 偶联连接子 |
CN115160403A (zh) * | 2022-07-05 | 2022-10-11 | 上海彩迩文生化科技有限公司 | 特异性拓扑异构酶抑制剂和可用于抗体药物偶联物及其制备方法 |
WO2024012566A2 (en) | 2022-07-15 | 2024-01-18 | Genequantum Healthcare (Suzhou) Co., Ltd. | Antibody, linkers, payload, conjugates and applications thereof |
WO2024020536A1 (en) * | 2022-07-22 | 2024-01-25 | Nj Bio, Inc. | Hexacyclic topoisomerase inhibitors having cytotoxic activity on cancer cells |
WO2024022372A1 (zh) * | 2022-07-27 | 2024-02-01 | 明慧医药(杭州)有限公司 | 抗体药物偶联物及其应用 |
TW202412859A (zh) | 2022-07-28 | 2024-04-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及雙特異性檢查點抑制劑之組合 |
CN117510515A (zh) * | 2022-07-28 | 2024-02-06 | 明慧医药(杭州)有限公司 | 适用于抗体-药物偶联物的毒素分子 |
US20240116945A1 (en) * | 2022-09-02 | 2024-04-11 | Merck Sharp & Dohme Llc | Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof |
WO2024073436A2 (en) * | 2022-09-26 | 2024-04-04 | Solve Therapeutics, Inc. | Compositions and uses thereof |
WO2024067811A1 (en) * | 2022-09-30 | 2024-04-04 | Beigene, Ltd. | Ligand-drug conjugate of exatecan analogue, and medical use thereof |
US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
WO2024091437A1 (en) | 2022-10-25 | 2024-05-02 | Merck Sharp & Dohme Llc | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof |
WO2024110905A1 (en) | 2022-11-24 | 2024-05-30 | Beigene, Ltd. | Anti-cea antibody drug conjugates and methods of use |
WO2024109949A1 (zh) * | 2022-11-25 | 2024-05-30 | 明慧医药(杭州)有限公司 | 一种抗肿瘤化合物及其应用 |
WO2024114318A1 (zh) * | 2022-11-29 | 2024-06-06 | 四川科伦博泰生物医药股份有限公司 | 药物连接子化合物及其制备方法和用途 |
WO2024116094A1 (en) | 2022-11-30 | 2024-06-06 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugates and dnmt inhibitors |
WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
CN116621927B (zh) * | 2023-01-09 | 2024-03-26 | 联宁(苏州)生物制药有限公司 | 带有伊喜替康和C-lock定点偶联基团的抗体偶联中间体、偶联方法及抗体偶联药物 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
JP3008226B2 (ja) | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
US5658920A (en) | 1991-01-16 | 1997-08-19 | Daiichi Pharmaceutical Co., Ltd. | Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound |
JPH0559061U (ja) | 1991-04-18 | 1993-08-03 | 株式会社ケイヴイシー | ボールバルブ |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
EP0656941B1 (en) | 1992-03-24 | 2005-06-01 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
JP3359955B2 (ja) | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
JPH0687746U (ja) | 1993-06-02 | 1994-12-22 | 株式会社ユニシアジェックス | 液圧緩衝器のリザーバチューブ構造 |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
CA2177367A1 (en) | 1993-12-03 | 1995-06-08 | Andrew David Griffiths | Recombinant binding proteins and peptides |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
JPH08337584A (ja) | 1995-04-10 | 1996-12-24 | Dai Ichi Seiyaku Co Ltd | 縮合六環式アミノ化合物、これを含有する医薬及びその製法 |
SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
JPH1095802A (ja) * | 1995-12-28 | 1998-04-14 | Tanabe Seiyaku Co Ltd | カンプトテシン誘導体 |
CA2192725C (en) | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
TW409058B (en) | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
JPH1171280A (ja) | 1997-06-26 | 1999-03-16 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
JPH1192405A (ja) | 1997-09-19 | 1999-04-06 | Dai Ichi Seiyaku Co Ltd | 薬物複合体 |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
CN1250293C (zh) * | 1998-05-22 | 2006-04-12 | 第一制药株式会社 | 药物复合物 |
IL142842A0 (en) | 1998-10-30 | 2002-03-10 | Daiichi Seiyaku Co | Dds compounds and method for assaying the same |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
JP2002060351A (ja) | 2000-03-22 | 2002-02-26 | Dai Ichi Seiyaku Co Ltd | 水酸基を有する薬物を含むdds化合物 |
MXPA02012791A (es) | 2000-06-29 | 2003-12-11 | Daiichi Seiyaku Co | Compuestos dds y metodo para prepararlo. |
CA2415922A1 (en) | 2000-07-13 | 2002-01-24 | Daiichi Pharmaceutical Co., Ltd. | Pharmaceutical compositions containing dds compound |
EP2314686B2 (en) | 2000-10-06 | 2023-06-21 | Kyowa Kirin Co., Ltd. | Cells producing antibody compositions |
US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
TWI313609B (en) * | 2001-08-21 | 2009-08-21 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
HU230378B1 (hu) | 2001-11-01 | 2016-03-29 | Uab Research Foundation | Anti-DR5 ellenanyagok és anti-DR4 ellenanyagok és más terápiás ágensek kombinációi |
US20050123536A1 (en) | 2001-11-20 | 2005-06-09 | Che-Leung Law | Treatment of immunological disorders using anti-dc30 antibodies |
US7585491B2 (en) | 2002-12-13 | 2009-09-08 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
JP2007527872A (ja) | 2004-02-26 | 2007-10-04 | イノテック ファーマシューティカルズ コーポレイション | イソキノリン誘導体及びその使用方法 |
AU2005218642B2 (en) | 2004-03-02 | 2011-04-28 | Seagen Inc. | Partially loaded antibodies and methods of their conjugation |
NZ550934A (en) * | 2004-05-19 | 2010-05-28 | Medarex Inc | Chemical linkers and conjugates thereof |
BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
EP1817341A2 (en) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
DE102005009099A1 (de) | 2005-02-28 | 2006-08-31 | Ktb Tumorforschungsgesellschaft Mbh | Proteinbindende Camptothecin-Peptid-Derivate und diese enthaltende Arzneimittel |
DE102005009084A1 (de) | 2005-02-28 | 2006-08-31 | Ktb Tumorforschungsgesellschaft Mbh | Proteinbindende Anthrazyklin-Peptid-Derivate und diese enthaltende Arzneimittel |
AU2006236225C1 (en) | 2005-04-19 | 2013-05-02 | Seagen Inc. | Humanized anti-CD70 binding agents and uses thereof |
US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
CN101490087B (zh) * | 2006-05-30 | 2013-11-06 | 健泰科生物技术公司 | 抗体和免疫偶联物及其用途 |
EP2446904B1 (en) | 2006-05-30 | 2015-04-29 | Genentech, Inc. | Anti-CD22 antibodies, their immunoconjugates and uses thereof |
ITMI20061473A1 (it) | 2006-07-26 | 2008-01-27 | Indena Spa | Derivati della camptotecina ad attivita antitumorale |
WO2008079293A1 (en) | 2006-12-21 | 2008-07-03 | Schering Corporation | Pyrrolo [3, 2-a] pyridine derivatives for inhibiting ksp kinesin activity |
JP2010523478A (ja) * | 2007-03-22 | 2010-07-15 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | モノクローナル抗体8h9の使用 |
CN104524590B (zh) | 2008-04-30 | 2019-06-21 | 伊缪诺金公司 | 交联剂和它们的用途 |
PT3912643T (pt) | 2009-02-13 | 2023-01-12 | Immunomedics Inc | Imunoconjugados com uma ligação intracelular clivável |
JP5829520B2 (ja) | 2009-08-20 | 2015-12-09 | 国立大学法人 千葉大学 | コルヒチン誘導体 |
JP2013505944A (ja) | 2009-09-24 | 2013-02-21 | シアトル ジェネティックス, インコーポレイテッド | Dr5リガンド薬物結合体 |
CN103079587B (zh) | 2010-05-13 | 2016-05-11 | 印第安纳大学研究及科技有限公司 | 呈现核激素受体活性的胰高血糖素超家族肽 |
EA035193B1 (ru) | 2010-05-18 | 2020-05-14 | Серулин Фарма Инк. | Композиции и способы лечения аутоиммунных и других заболеваний |
JP5913307B2 (ja) | 2010-07-12 | 2016-04-27 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 多機能性抗体複合体 |
JP5889912B2 (ja) | 2010-11-17 | 2016-03-22 | ジェネンテック, インコーポレイテッド | アラニニルメイタンシノール抗体コンジュゲート |
US20150023989A1 (en) | 2011-12-14 | 2015-01-22 | Seattle Genetics, Inc. | New antibody drug conjugates (adcs) and the use thereof |
US20130280282A1 (en) | 2012-04-24 | 2013-10-24 | Daiichi Sankyo Co., Ltd. | Dr5 ligand drug conjugates |
WO2013188740A1 (en) | 2012-06-14 | 2013-12-19 | Ambrx, Inc. | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides |
US9517522B2 (en) * | 2012-09-05 | 2016-12-13 | Illinois Tool Works Inc. | Self-aligning wire feeder assembly |
HUE039000T2 (hu) | 2012-10-11 | 2018-12-28 | Daiichi Sankyo Co Ltd | Antitest-gyógyszer konjugát |
EP2910573B1 (en) * | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
WO2014107024A1 (ko) | 2013-01-03 | 2014-07-10 | 셀트리온 | 항체-링커-약물 결합체, 그의 제조방법 및 그를 포함하는 항암제 조성물 |
CN103313390B (zh) | 2013-07-05 | 2016-01-20 | 江苏大学 | 一种基于双移动信标的wsn定位方法 |
DK3466976T3 (da) * | 2014-01-31 | 2021-12-13 | Daiichi Sankyo Co Ltd | Anti-her2-antistof-lægemiddelkonjugat |
US11185594B2 (en) | 2014-04-10 | 2021-11-30 | Daiichi Sankyo Company, Limited | (Anti-HER2 antibody)-drug conjugate |
KR102199434B1 (ko) | 2017-02-24 | 2021-01-06 | 장길훈 | 대화형 애플리케이션의 메시지 공유 시스템과 방법 |
-
2013
- 2013-10-10 HU HUE13845596A patent/HUE039000T2/hu unknown
- 2013-10-10 CA CA3021435A patent/CA3021435C/en active Active
- 2013-10-10 EP EP18152381.2A patent/EP3342785B1/en active Active
- 2013-10-10 LT LTEP13845596.9T patent/LT2907824T/lt unknown
- 2013-10-10 KR KR1020187007575A patent/KR101901558B1/ko active IP Right Grant
- 2013-10-10 PT PT138455969T patent/PT2907824T/pt unknown
- 2013-10-10 BR BR122021014365-0A patent/BR122021014365B1/pt active IP Right Grant
- 2013-10-10 KR KR1020217034817A patent/KR102369419B1/ko active IP Right Grant
- 2013-10-10 PL PL13845596T patent/PL2907824T3/pl unknown
- 2013-10-10 KR KR1020207006240A patent/KR102237639B1/ko active IP Right Grant
- 2013-10-10 SI SI201331006T patent/SI2907824T1/en unknown
- 2013-10-10 KR KR1020227022424A patent/KR102456726B1/ko active IP Right Grant
- 2013-10-10 BR BR112015006521-0A patent/BR112015006521B1/pt active IP Right Grant
- 2013-10-10 NZ NZ74644013A patent/NZ746440A/en unknown
- 2013-10-10 WO PCT/JP2013/006069 patent/WO2014057687A1/ja active Application Filing
- 2013-10-10 KR KR1020187026771A patent/KR102052319B1/ko active IP Right Grant
- 2013-10-10 RU RU2015113767A patent/RU2664465C2/ru active
- 2013-10-10 KR KR1020227006326A patent/KR102417310B1/ko active IP Right Grant
- 2013-10-10 JP JP2014540755A patent/JP5953378B2/ja active Active
- 2013-10-10 MX MX2015003903A patent/MX364484B/es active IP Right Grant
- 2013-10-10 ES ES13845596.9T patent/ES2671644T3/es active Active
- 2013-10-10 KR KR1020157007536A patent/KR101841818B1/ko active IP Right Grant
- 2013-10-10 NZ NZ74643913A patent/NZ746439A/en unknown
- 2013-10-10 IL IL271760A patent/IL271760B/en unknown
- 2013-10-10 TR TR2018/09636T patent/TR201809636T4/tr unknown
- 2013-10-10 RS RS20180643A patent/RS57278B1/sr unknown
- 2013-10-10 CN CN201810950717.0A patent/CN109081871B/zh active Active
- 2013-10-10 CN CN202211490738.1A patent/CN115960111A/zh active Pending
- 2013-10-10 EP EP19206764.3A patent/EP3632471A1/en active Pending
- 2013-10-10 MY MYPI2015000898A patent/MY170251A/en unknown
- 2013-10-10 CA CA2885800A patent/CA2885800C/en active Active
- 2013-10-10 IL IL302494A patent/IL302494B1/en unknown
- 2013-10-10 KR KR1020217009640A patent/KR102320907B1/ko active IP Right Grant
- 2013-10-10 DK DK13845596.9T patent/DK2907824T3/en active
- 2013-10-10 AU AU2013328111A patent/AU2013328111B2/en active Active
- 2013-10-10 IL IL313147A patent/IL313147A/en unknown
- 2013-10-10 DK DK18152381.2T patent/DK3342785T3/da active
- 2013-10-10 NZ NZ705394A patent/NZ705394A/en unknown
- 2013-10-10 LT LTEP18152381.2T patent/LT3342785T/lt unknown
- 2013-10-10 HU HUE18152381A patent/HUE048748T2/hu unknown
- 2013-10-10 SI SI201331658T patent/SI3342785T1/sl unknown
- 2013-10-10 ES ES18152381T patent/ES2773710T3/es active Active
- 2013-10-10 EP EP13845596.9A patent/EP2907824B1/en active Active
- 2013-10-10 PT PT181523812T patent/PT3342785T/pt unknown
- 2013-10-10 KR KR1020227035813A patent/KR102498405B1/ko active IP Right Grant
- 2013-10-10 IL IL294622A patent/IL294622B2/en unknown
- 2013-10-10 BR BR122021014396-0A patent/BR122021014396B1/pt active IP Right Grant
- 2013-10-10 KR KR1020237004110A patent/KR102540419B1/ko active IP Right Grant
- 2013-10-10 RS RS20200226A patent/RS60000B1/sr unknown
- 2013-10-10 KR KR1020197035246A patent/KR102087017B1/ko active IP Right Grant
- 2013-10-10 KR KR1020237018596A patent/KR102584005B1/ko active IP Right Grant
- 2013-10-10 CN CN202111179342.0A patent/CN113929738B/zh active Active
- 2013-10-10 SG SG11201502887WA patent/SG11201502887WA/en unknown
- 2013-10-10 PL PL18152381T patent/PL3342785T3/pl unknown
- 2013-10-10 SG SG10201804788XA patent/SG10201804788XA/en unknown
- 2013-10-10 KR KR1020237032467A patent/KR20230142808A/ko active IP Right Grant
- 2013-10-10 US US14/435,114 patent/US10195288B2/en active Active
- 2013-10-10 CN CN201380053256.2A patent/CN104755494B/zh active Active
- 2013-10-10 NZ NZ74094813A patent/NZ740948A/en unknown
- 2013-10-11 TW TW108100079A patent/TWI696611B/zh active
- 2013-10-11 TW TW111105275A patent/TW202233186A/zh unknown
- 2013-10-11 TW TW109116005A patent/TWI757740B/zh active
- 2013-10-11 TW TW102136742A patent/TWI615152B/zh active
- 2013-10-11 TW TW107100508A patent/TWI650312B/zh active
-
2015
- 2015-03-17 ZA ZA2015/01825A patent/ZA201501825B/en unknown
- 2015-03-25 PH PH12015500667A patent/PH12015500667B1/en unknown
- 2015-03-26 MX MX2020010964A patent/MX2020010964A/es unknown
- 2015-03-26 MX MX2019004502A patent/MX2019004502A/es unknown
- 2015-04-02 IL IL238143A patent/IL238143B/en active IP Right Grant
- 2015-11-12 HK HK15111165.9A patent/HK1210477A1/xx unknown
-
2016
- 2016-06-13 JP JP2016117096A patent/JP6186045B2/ja active Active
- 2016-06-13 US US15/180,203 patent/US9808537B2/en active Active
- 2016-08-09 JP JP2016156697A patent/JP6030267B1/ja active Active
-
2017
- 2017-07-28 JP JP2017146257A patent/JP6371452B2/ja active Active
-
2018
- 2018-01-12 AU AU2018200308A patent/AU2018200308B2/en active Active
- 2018-06-05 HR HRP20180870TT patent/HRP20180870T1/hr unknown
- 2018-06-26 CY CY20181100657T patent/CY1120363T1/el unknown
- 2018-07-04 PH PH12018501433A patent/PH12018501433A1/en unknown
- 2018-07-12 JP JP2018131996A patent/JP6715888B2/ja active Active
- 2018-09-26 US US16/142,354 patent/US10973924B2/en active Active
- 2018-12-10 HK HK18115765.1A patent/HK1256631A1/zh unknown
-
2019
- 2019-02-08 ZA ZA2019/00820A patent/ZA201900820B/en unknown
-
2020
- 2020-01-24 AU AU2020200548A patent/AU2020200548B2/en active Active
- 2020-03-03 HR HRP20200353TT patent/HRP20200353T1/hr unknown
- 2020-03-19 CY CY20201100256T patent/CY1122789T1/el unknown
- 2020-03-24 US US16/828,279 patent/US11633493B2/en active Active
- 2020-06-09 JP JP2020100531A patent/JP6952835B2/ja active Active
-
2021
- 2021-09-28 JP JP2021157523A patent/JP7170812B2/ja active Active
-
2022
- 2022-05-26 AU AU2022203560A patent/AU2022203560A1/en active Pending
-
2023
- 2023-03-03 US US18/117,089 patent/US20240082413A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201900820B (en) | Antibody-drug conjugate | |
HUS2300020I1 (hu) | Pirrolobenzodiazepin-antitest konjugátumok | |
HRP20190056T1 (hr) | Konjugat anti-trop2 antitijelo-lijek | |
ZA201502523B (en) | Pyrrolobenzodiazepine-anitbody conjugates | |
EP2920167A4 (en) | HYDRAZINYL-INDOLES AND CONJUGATED COMPOUNDS | |
SG10201605401WA (en) | Antibody-drug conjugates | |
EP2928902A4 (en) | conjugate compounds | |
IL234604A (en) | Carbon-glycophide vaccines are vaccinated | |
ZA201409119B (en) | Polymer-nsaid conjugate |